HomeCompareLBTSF vs ARCC

LBTSF vs ARCC: Dividend Comparison 2026

LBTSF yields 1.34% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBTSF wins by $12.87M in total portfolio value· pulled ahead in Year 3
10 years
LBTSF
LBTSF
● Live price
1.34%
Share price
$15.35
Annual div
$0.21
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.89M
Annual income
$11,275,798.89
Full LBTSF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — LBTSF vs ARCC

📍 LBTSF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBTSFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBTSF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBTSF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBTSF
Annual income on $10K today (after 15% tax)
$114.07/yr
After 10yr DRIP, annual income (after tax)
$9,584,429.06/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, LBTSF beats the other by $9,584,428.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBTSF + ARCC for your $10,000?

LBTSF: 50%ARCC: 50%
100% ARCC50/50100% LBTSF
Portfolio after 10yr
$6.46M
Annual income
$5,637,900.02/yr
Blended yield
87.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

LBTSF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.0
Piotroski
7/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBTSF buys
0
ARCC buys
0
No recent congressional trades found for LBTSF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBTSFARCC
Forward yield1.34%10.82%
Annual dividend / share$0.21$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$12.89M$24.5K
Annual income after 10y$11,275,798.89$1.16
Total dividends collected$12.74M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: LBTSF vs ARCC ($10,000, DRIP)

YearLBTSF PortfolioLBTSF Income/yrARCC PortfolioARCC Income/yrGap
1$10,968$268.40$11,381$541.15$413.00ARCC
2$12,286$550.27$12,621$284.08$335.00ARCC
3← crossover$14,299$1,152.15$13,827$145.31+$472.00LBTSF
4$17,806$2,506.24$15,062$73.43+$2.7KLBTSF
5$24,886$5,833.59$16,364$36.89+$8.5KLBTSF
6$41,867$15,239.53$17,757$18.49+$24.1KLBTSF
7$92,721$47,922.73$19,258$9.25+$73.5KLBTSF
8$297,587$198,376.17$20,880$4.63+$276.7KLBTSF
9$1,508,490$1,190,071.76$22,636$2.32+$1.49MLBTSF
10$12,889,884$11,275,798.89$24,539$1.16+$12.87MLBTSF

LBTSF vs ARCC: Complete Analysis 2026

LBTSFStock

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Full LBTSF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this LBTSF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBTSF vs SCHDLBTSF vs JEPILBTSF vs OLBTSF vs KOLBTSF vs MAINLBTSF vs HTGCLBTSF vs GBDCLBTSF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.